IL166552A0 - Pyrimidine derivatives and their use as cb2 modulators - Google Patents

Pyrimidine derivatives and their use as cb2 modulators

Info

Publication number
IL166552A0
IL166552A0 IL16655205A IL16655205A IL166552A0 IL 166552 A0 IL166552 A0 IL 166552A0 IL 16655205 A IL16655205 A IL 16655205A IL 16655205 A IL16655205 A IL 16655205A IL 166552 A0 IL166552 A0 IL 166552A0
Authority
IL
Israel
Prior art keywords
modulators
pyrimidine derivatives
pyrimidine
derivatives
Prior art date
Application number
IL16655205A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31948030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL166552(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0219501A external-priority patent/GB0219501D0/en
Priority claimed from GB0309326A external-priority patent/GB0309326D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL166552A0 publication Critical patent/IL166552A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL16655205A 2002-08-21 2005-01-27 Pyrimidine derivatives and their use as cb2 modulators IL166552A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0219501A GB0219501D0 (en) 2002-08-21 2002-08-21 Compounds
GB0309326A GB0309326D0 (en) 2003-04-24 2003-04-24 Compounds
PCT/EP2003/009217 WO2004018433A1 (fr) 2002-08-21 2003-08-19 Derives de pyrimidine et leur utilisation en tant que modulateurs cb2

Publications (1)

Publication Number Publication Date
IL166552A0 true IL166552A0 (en) 2006-01-15

Family

ID=31948030

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16655205A IL166552A0 (en) 2002-08-21 2005-01-27 Pyrimidine derivatives and their use as cb2 modulators
IL185549A IL185549A0 (en) 2002-08-21 2007-08-27 Pyrimidine derivatives and their use as cb2 modulators

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL185549A IL185549A0 (en) 2002-08-21 2007-08-27 Pyrimidine derivatives and their use as cb2 modulators

Country Status (35)

Country Link
US (2) US7635701B2 (fr)
EP (2) EP1539712B1 (fr)
JP (1) JP4583174B2 (fr)
KR (1) KR20050058367A (fr)
CN (1) CN100351239C (fr)
AP (1) AP2005003219A0 (fr)
AR (1) AR041016A1 (fr)
AT (2) ATE377591T1 (fr)
AU (1) AU2003264076B2 (fr)
BR (1) BR0313676A (fr)
CA (1) CA2495880C (fr)
CY (1) CY1107871T1 (fr)
DE (2) DE60317348T2 (fr)
DK (1) DK1539712T3 (fr)
EA (2) EA010130B1 (fr)
EC (1) ECSP055613A (fr)
ES (1) ES2295682T3 (fr)
HK (1) HK1079193A1 (fr)
IL (2) IL166552A0 (fr)
IS (1) IS7749A (fr)
MA (1) MA27428A1 (fr)
MX (1) MXPA05001960A (fr)
MY (1) MY137053A (fr)
NO (1) NO20051451D0 (fr)
NZ (1) NZ537886A (fr)
OA (1) OA12910A (fr)
PE (1) PE20040898A1 (fr)
PL (1) PL376047A1 (fr)
PT (1) PT1539712E (fr)
SI (1) SI1539712T1 (fr)
TW (1) TW200410946A (fr)
UA (1) UA83194C2 (fr)
UY (1) UY27939A1 (fr)
WO (1) WO2004018433A1 (fr)
ZA (1) ZA200500913B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27939A1 (es) * 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
WO2004029204A2 (fr) 2002-09-27 2004-04-08 Merck & Co., Inc. Pyrimidines substituees
TW200505902A (en) * 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
US20040259887A1 (en) * 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
GB0402355D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
GB0402356D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
WO2005096784A2 (fr) 2004-04-08 2005-10-20 Targegen, Inc. Inhibiteurs benzotriazine de kinases
AU2005276974B2 (en) 2004-08-25 2012-08-02 Targegen, Inc. Heterocyclic compounds and methods of use
GB0517188D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
NZ592990A (en) 2005-11-01 2013-01-25 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
JP2009519349A (ja) * 2005-12-15 2009-05-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を変調する化合物
JP2009536613A (ja) * 2006-04-07 2009-10-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
WO2008014199A2 (fr) 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Composés modulant le récepteur cb2
EP2070927A4 (fr) 2006-09-13 2010-10-13 Kyowa Hakko Kirin Co Ltd Dérivé hétérocyclique fusionné
CN101516839A (zh) 2006-09-25 2009-08-26 贝林格尔.英格海姆国际有限公司 调节cb2受体的化合物
EP2076499B1 (fr) 2006-10-04 2010-05-12 F.Hoffmann-La Roche Ag Dérivés de pyrazine-2-carboxamide en tant que modulateurs du récepteur cb2
WO2008048914A1 (fr) * 2006-10-17 2008-04-24 Boehringer Ingelheim International Gmbh Composés qui modulent le récepteur cb2
WO2008075353A1 (fr) 2006-12-19 2008-06-26 Pharmos Corporation Dérivés sulfonamides avec indications thérapeutiques
GB0705803D0 (en) * 2007-03-28 2007-05-02 Glaxo Group Ltd Novel compounds
KR20100100858A (ko) * 2007-11-06 2010-09-15 에모리 유니버시티 안전한 ｎｍｄａ 수용체 길항제의 식별 방법
CA2704684A1 (fr) 2007-11-07 2009-05-14 Boehringer Ingelheim International Gmbh Composes modulant le recepteur cb2
JP5749162B2 (ja) 2008-07-10 2015-07-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節するスルホン化合物
EP2342200B1 (fr) 2008-09-25 2013-01-23 Boehringer Ingelheim International GmbH Composés modulant sélectivement le récepteur cb2
TW201031650A (en) * 2008-12-02 2010-09-01 Organon Nv 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione
TW201031649A (en) 2008-12-02 2010-09-01 Organon Nv 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives
AU2010231694A1 (en) * 2009-03-30 2011-10-06 Astellas Pharma Inc. Pyrimidine compound
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
EP2443107B1 (fr) 2009-06-16 2018-08-08 Boehringer Ingelheim International GmbH Dérivés d'azétidine 2-carboxamide qui modulent le récepteur cb2
US8383651B2 (en) 2009-09-22 2013-02-26 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
EP2523936A1 (fr) 2010-01-15 2012-11-21 Boehringer Ingelheim International GmbH Composés qui modulent le récepteur cb2
EP2542539B1 (fr) 2010-03-05 2014-02-26 Boehringer Ingelheim International GmbH Composés tétrazoles qui modulent sélectivement le récepteur cb2
JP5746764B2 (ja) 2010-07-22 2015-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
WO2012014963A1 (fr) * 2010-07-29 2012-02-02 アステラス製薬株式会社 Composé de pyridine à cycle condensé
WO2012060847A1 (fr) 2010-11-07 2012-05-10 Targegen, Inc. Compositions et procédés de traitement de la myélofibrose
US20150261260A1 (en) * 2013-03-15 2015-09-17 Royce J. Nicholas Method of water-proofing electronic components
EP2803668A1 (fr) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Nouveau (cyano-dimethyl-methyl)-isoxazoles et - [1,3,4] thiadiazoles
KR102313314B1 (ko) * 2013-10-23 2021-10-19 아카데미아 시니카 신경퇴행성 질환 및 통증의 예방 및 치료에 사용하기 위한 화합물
WO2017185038A1 (fr) 2016-04-22 2017-10-26 Receptor Life Sciences Composés médicinaux à base de plantes à action rapide, et suppléments nutritionnels
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5518A (en) 1848-04-18 Geaijst-drieb
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
FR2634376B1 (fr) 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
IT1227626B (it) 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
US5112820A (en) 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
HUT63941A (en) * 1992-05-15 1993-11-29 Hoechst Ag Process for producing 4-alkyl-substituted pyrimidine-5-carboxanilide derivatives, and fungicidal compositions comprising same
DK0644755T3 (da) 1992-06-10 1997-09-22 Nanosystems Llc Overflademodificerede NSAID-nanopartikler
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
CZ101496A3 (en) 1993-10-12 1996-11-13 Du Pont Merck Pharma N-alkyl-n-aryl-pyrimidinamines and derivatives thereof
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5571536A (en) 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5560931A (en) 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en) 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
PL185544B1 (pl) 1995-02-13 2003-05-30 Nowa pochodna podstawionego izoksazolu i środek farmaceutyczny
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
CA2230894A1 (fr) * 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Carboxamides de pyrimidine et composes associes, et methodes de traitement d'etats inflammatoires
US5811428A (en) * 1995-12-18 1998-09-22 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
US6576264B1 (en) 1995-10-17 2003-06-10 Skyepharma Canada Inc. Insoluble drug delivery
FR2742148B1 (fr) 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
CA2249009C (fr) 1996-04-12 2003-09-16 G.D. Searle & Co. Derives benzenesulfonamide substitue utilisables comme precurseurs des inhibiteurs du cox-2
CZ292843B6 (cs) 1996-07-18 2003-12-17 Merck Frosst Canada & Co. Derivát pyridinu a farmaceutický prostředek s jeho obsahem
WO1998035666A1 (fr) 1997-02-13 1998-08-20 Nanosystems Llc Preparation de pastilles de naproxene nanoparticulaire
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
DE69833464T2 (de) 1997-09-05 2006-08-24 Glaxo Group Ltd., Greenford Pharmazeutische Zusammensetzung, enthaltend 2,3-Diaryl-PyrazoloÄ1,5-bÜPyridazin Derivate
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
IL140276A0 (en) 1998-06-19 2002-02-10 Rtp Pharma Inc Processes to generate submicron particles of water-insoluble compounds
CA2346001C (fr) 1998-10-01 2003-12-30 Elan Pharma International, Limited Liberation regulee de compositions nanoparticulaires
KR20010075673A (ko) 1998-11-03 2001-08-09 그레이엄 브레레톤, 레슬리 에드워즈 선택적 ｃｏｘ-2 억제제로서의 피라졸로피리딘 유도체
US6180136B1 (en) 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
IL143196A0 (en) 1998-11-20 2002-04-21 Rtp Pharma Inc Method of preparing stable suspensions of insoluble microparticles
US6025683A (en) 1998-12-23 2000-02-15 Stryker Corporation Motor control circuit for regulating a D.C. motor
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6498166B1 (en) 1999-02-27 2002-12-24 Smithkline Beecham Corporation Pyrazolopyridines
GB9927844D0 (en) * 1999-11-26 2000-01-26 Glaxo Group Ltd Chemical compounds
CO5261556A1 (es) 1999-12-08 2003-03-31 Pharmacia Corp Composiciones inhibidoras de ciclooxigenasa-2 que tiene rapido acceso de efecto terapeutico
GB0003224D0 (en) * 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
PL202623B1 (pl) 2000-06-28 2009-07-31 Smithkline Beecham Plc Sposób wytwarzania drobno zmielonego preparatu substancji leczniczej, drobno zmielona substancja lecznicza wytworzona tym sposobem i zawierająca ją kompozycja farmaceutyczna
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
WO2002018380A1 (fr) 2000-08-31 2002-03-07 F. Hoffmann-La Roche Ag 7 oxo pyridopyrimidines comme inhibiteurs d'une proliferation cellulaire
GB0021494D0 (en) 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
EP1363632B1 (fr) 2001-01-29 2010-08-25 The University of Connecticut Aminoalkylindoles cannabimimetiques selectifs d'un recepteur
US7507767B2 (en) 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
JP2005508833A (ja) 2001-02-20 2005-04-07 ブリストル−マイヤーズ　スクイブ　カンパニー Ｋｃｎｑカリウムチャネル・モジュレーターとしての２，４−ジ置換ピリミジン−５−カルボキサミド誘導体
FR2839718B1 (fr) 2002-05-17 2004-06-25 Sanofi Synthelabo Derives d'indole, leur procede de preparation et les compositions pharmaceutiques en contenant
CN1662496A (zh) 2002-06-19 2005-08-31 先灵公司 大麻素受体激动剂
AU2003244098A1 (en) 2002-06-28 2004-01-19 Yamanouchi Pharmaceutical Co., Ltd. Diaminopyrimidinecarboxa mide derivative
UY27939A1 (es) * 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
EP1534687B1 (fr) 2002-08-21 2006-09-27 Glaxo Group Limited Derives de 2-phenylamino-4-trifluoromethyl-5-(benzyl- ou pyridin-4-ylmethyl)carbamoylpyrimidine comme modulateurs selectifs du recepteur cannabinoide cb2
WO2004029204A2 (fr) 2002-09-27 2004-04-08 Merck & Co., Inc. Pyrimidines substituees
GB0222493D0 (en) 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
GB0222495D0 (en) 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands

Also Published As

Publication number Publication date
EP1539712A1 (fr) 2005-06-15
ZA200500913B (en) 2006-07-26
US7635701B2 (en) 2009-12-22
CN1688552A (zh) 2005-10-26
BR0313676A (pt) 2005-06-21
DK1539712T3 (da) 2008-03-17
NZ537886A (en) 2007-05-31
SI1539712T1 (sl) 2008-04-30
TW200410946A (en) 2004-07-01
ECSP055613A (es) 2005-04-18
IS7749A (is) 2005-03-17
MA27428A1 (fr) 2005-07-01
PE20040898A1 (es) 2005-01-07
EP1878725B1 (fr) 2010-11-24
UA83194C2 (ru) 2008-06-25
EA200700934A1 (ru) 2007-08-31
AP2005003219A0 (en) 2005-03-31
CY1107871T1 (el) 2013-06-19
HK1079193A1 (en) 2006-03-31
NO20051451L (no) 2005-03-18
ES2295682T3 (es) 2008-04-16
MXPA05001960A (es) 2005-04-28
JP2006501228A (ja) 2006-01-12
EA012703B1 (ru) 2009-12-30
MY137053A (en) 2008-12-31
ATE377591T1 (de) 2007-11-15
EA010130B1 (ru) 2008-06-30
DE60335151D1 (de) 2011-01-05
KR20050058367A (ko) 2005-06-16
PT1539712E (pt) 2008-02-08
PL376047A1 (en) 2005-12-12
UY27939A1 (es) 2004-03-31
EP1878725A3 (fr) 2008-01-30
DE60317348D1 (de) 2007-12-20
US20060293354A1 (en) 2006-12-28
JP4583174B2 (ja) 2010-11-17
AU2003264076A1 (en) 2004-03-11
EP1878725A2 (fr) 2008-01-16
AR041016A1 (es) 2005-04-27
AU2003264076B2 (en) 2007-09-20
US20100041654A1 (en) 2010-02-18
CA2495880C (fr) 2010-04-27
OA12910A (en) 2006-10-13
IL185549A0 (en) 2008-01-06
CN100351239C (zh) 2007-11-28
CA2495880A1 (fr) 2004-03-04
EP1539712B1 (fr) 2007-11-07
NO20051451D0 (no) 2005-03-18
ATE489369T1 (de) 2010-12-15
DE60317348T2 (de) 2008-08-28
EA200500392A1 (ru) 2005-08-25
WO2004018433A1 (fr) 2004-03-04

Similar Documents

Publication Publication Date Title
IL185549A0 (en) Pyrimidine derivatives and their use as cb2 modulators
SI1487805T1 (sl) Pirimidinski derivati
AP2004003110A0 (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials
EP1546115A4 (fr) Pyrimidines substituees
AU2003266321A1 (en) Tetrahydropyrimidine-2-one derivatives and their uses
TWI349671B (en) Novel adenine derivative and its use
HK1091488A1 (en) Pyrimidine derivatives
PL375390A1 (en) 4-trifluoromethylpyrazolyl substituted pyridines and pyrimidines
PL375395A1 (en) 4-trifluoromethylpyrazolyl substituted pyridines and pyrimidines
IL163940A0 (en) Aryl substituted pyrimidines and the use thereof
AU2003249909A1 (en) Phenoxypropenylphenyl derivatives and their use as herbicides
IL182136A0 (en) Novel pyrimidine derivatives and their use as ppar-alpha modulators
IL163868A0 (en) Hermiasterlin derivatives and uses thereof
AU2003202091A8 (en) Guanidine derivatives
AU2003216221A1 (en) Attachment and articles using same
GB0220214D0 (en) Compounds and their use
AU2003206694A1 (en) Substituted alkyl uracils and the use thereof
AU2003297612A8 (en) 2-substituted-3-propenamide derivatives and methods of using the same
EP1553101A4 (fr) Derives de n-acetylglucosamine et utilisation
AU2002368112A1 (en) Pyrimidine derivatives
AU2003215379A1 (en) Substituted pyrimidinones and pyrimidinthiones
AU2003205963A1 (en) Azaphenylalanine derivatives and their use as antithrombotic agents
GB0307231D0 (en) 7-Nitroindoline derivatives and their uses
AU2003236937A1 (en) School supply - universal
GB0227443D0 (en) Pyrimidine derivatives